What obesity drugmakers see next in the market: More pills, easier access and drug combinations

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...
abc7NY

Pfizer's COVID-19 pill reduces risk of being hospitalized or dying by 89%, company says

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
ABC 10 News

FDA authorizes pharmacists to prescribe Pfizer's pill to treat COVID-19

The Food and Drug Administration announced Wednesday that state-licensed pharmacists can now prescribe Paxlovid. The pill, developed by Pfizer, is used to treat mild-to-moderate COVID-19. “Since ...
WTVF

Pfizer: Final trial results show anti-COVID-19 pill reduces death, hospitalizations by 89%

Pfizer said Tuesday morning that final trial studies still show its experimental COVID-19 pill significantly reduced the risk of hospitalization or death linked to the virus by 89%. The company also ...

Expect a busy year in obesity drugs as new pills hit the market

Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.
GlobalData on MSN

NICE greenlights Pfizer’s Talzenna for NHS use

NICE now recommends NHS use of the daily pill to patients with metastatic prostate cancer.
NBC 10 Philadelphia

Pfizer acquires obesity drug maker Metsea after a bidding war with Novo Nordisk

U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss ...